Skip to main content

Immunovant, Inc.

IMVT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001764013

In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.

Q4 2021 vs. Q3 2021

How the institutions holding Immunovant, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of IMVT: Q3 2021 compared with Q4 2021
MeasureQ3 2021Of which not filed for Q4 2021Q4 2021Change
Holders1192118+1
Shares33.8M54.6K37.8M+4.12M (+12.2%)
Value$293.6M$475.0K$322.4M+$29.3M (+10.0%)

2 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (21)

Institutions that held Immunovant, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to IMVT in Q4 2021
InstitutionSharesValue% of portfolio
Deep Track Capital, LP4,775,000$40.7M3.01%
Point72 Asset Management, L.P.900,500$7.67M0.03%
Octagon Capital Advisors LP572,862$4.88M0.95%
PDT Partners, LLC109,138$930.0K0.07%
Corton Capital Inc.35,623$304.0K0.13%
DuPont Capital Management Corp27,247$232.0K0.01%
Graham Capital Management, L.P.24,410$207.0K0.01%
HighTower Advisors, LLC24,247$206.0K0.00%
D. E. Shaw & Co., Inc.20,371$174.0K0.00%
Renaissance Technologies LLC17,600$150.0K0.00%
Quantbot Technologies LP16,213$138.0K0.01%
Virtu Financial LLC14,914$127.0K0.01%
Engineers Gate Manager LP13,733$117.0K0.01%
Delphia (USA) Inc.13,762$117.0K0.12%
Arizona State Retirement System10,833$92.0K0.00%
Ensign Peak Advisors, Inc3,680$31.0K0.00%
Aquatic Capital Management LLC1,900$16.0K0.03%
Captrust Financial Advisors670$6.00K0.00%
Point72 Hong Kong Ltd562$5.00K0.00%
Parallel Advisors, LLC382$3.00K0.00%
Umb Bank N A141$1.00K0.00%

Sold out (20)

Institutions that held Immunovant, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

Not filed for Q4 2021 yet (2)

Institutions that held Immunovant, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding IMVT in Q3 2021 that haven't filed for Q4 2021
InstitutionShares, Q3 2021Value, Q3 2021
Knott David M42,600$370.0K
Marshall Wace North America L.P.11,994$105.0K